Intrinsic Therapeutics Closes $49MM Financing

Intrinsic Therapeutics closed a US $49MM round of financing, which will support global commercialization of the Barricaid Anular Closure Device.

Barricaid is designed to prevent reherniation following lumbar discectomy surgery to treat sciatic pain caused by a herniated disc. In 4Q16, the company filed a Premarket Application with FDA based on...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us